CEO of Relay Therapeutics Buys Nearly 1,000 Shares at 85% Discount While Selling 43,000 Shares to Cover RSU Tax on New Award
Patel Sanjiv’s 2025‑26 insider trades show confident, long‑term support for Relay Therapeutics amid promising oncology data, signaling potential value for investors.
3 minutes to read